HC Wainwright & Co. Reiterates Buy on Ventyx Biosciences, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on Ventyx Biosciences (NASDAQ:VTYX) and maintained a $52 price target.
October 10, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ventyx Biosciences has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $52.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Ventyx Biosciences. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100